31 results about "Reticulocyte" patented technology

The invention discloses a reticulocyte recognition and grading system based on a blood smear, and particularly relates to the field of medical cell morphology examination, and the system comprises an image acquisition module, a staining normalization module, an instance segmentation module, an erythrocyte classification module, a reticulocyte grading module and a statistics output module. The image acquisition module adopts an automatic microscope platform to continuously scan the blood smear under a 100-time visual field, acquires a high-quality bright field channel image through an automatic focusing technology, and monitors image definition, contrast and illumination uniformity; the statistical output module is used for calculating the proportion and bluish violet intensity statistics of reticulocytes of each level, and generating a visual quality control result and a diagnostic report; according to the invention, full-automatic processing from samples to reports is realized, interpretability and high classification precision are both considered, subjective difference and omission ratio of manual microscopic examination are significantly reduced, and efficiency and consistency of clinical detection are improved.

Glycated Hb was measured in reticulocytes (RNA-positive cells) and was correlated to a decrease in RNA fluorescence intensity in a Log-linear dependent manner, with no statistically significant differences in slope or in the ordinate of the origin between individuals. The loss of RNA fluorescence intensity in reticulocytes observed by flow cytometry is directly related to the time they spend in circulation and consequently to their lifespan. By setting the time that reticulocytes spend to mature in the blood circulation and because the relation between the decrease in log RNA fluorescence intensity and the increase in log HbA1c fluorescence intensity is linear, the inventors are able to calculate the increase in HbA1c fluorescence intensity depending on the time and thus to determine the mean half-life of a RBC population. This new tool is noninvasive and requires only one single time point measurement. The present invention relates to a method for in vitro determination of the age of red blood cells of a set of red blood cells by using intracellular glycated hemoglobin measurement by flow cytometry and by using a standard curve generated from glycated hemoglobin measurement in reticulocyes.

The invention discloses an image processing method and device for judging suspension red blood cell hemolysis. The method comprises the following steps: acquiring a blood image set; the blood image set comprises a plurality of blood images and corresponding label information; acquiring a blood parameter information set; the blood parameter information set comprises a plurality of blood parameters and corresponding label information; the blood parameters comprise hemoglobin concentration, reticulocyte concentration, indirect bilirubin concentration, lactic dehydrogenase concentration and globin concentration; utilizing the blood image set and the blood parameter information set to construct a blood hemolysis composite detection model; based on the blood hemolysis composite detection model, processing the collected blood image and blood parameters to obtain hemolysis detection result information; the hemolysis detection result information is used for representing erythrocyte hemolysis information of the blood corresponding to the collected blood image and blood parameters.

A method for staining reticulocytes includes staining reagent A and stabilizing reagent B; stabilizing reagent B is used M seconds after staining reagent A is mixed with the sample; M is greater than or equal to 20 seconds; staining reagent A includes staining agent A10, adjusting salt C10, and water; staining agent A10 is neomethylene blue; the concentration of neomethylene blue in staining reagent A is 0.8 × 10⁻⁶. ‑4 g / ml ~ 8.0 × 10 ‑4 g / mL; adjusting salt C10 is used to provide a low osmotic pressure environment and a pH range of 7.0–8.0; stabilizing reagent B includes staining stabilizer B10, adjusting salt D10, and water; the staining stabilizer B10 in stabilizing reagent B includes aldehydes. A unique two-step reagent formulation and method are used to achieve rapid staining of reticulocytes in a step-by-step manner, achieving successful staining in just 20 seconds, and the staining effect can be maintained for a sufficiently long time, exceeding 120 minutes.

Provided are a method for preparing reticulocyte simulating particles and platelet simulating particles, and a reference control. The method for preparing the reticulocyte simulating particles comprises: staining mammalian anucleated red blood cells having a volume of 60-120 fL with a protein fluorescent dye activated by N-hydroxysuccinimide, and fixing the anucleated red blood cells to prepare the reticulocyte simulating particles. The platelet simulating particles are prepared from mammalian anucleated red blood cells having a volume of 2-25 fL, and the steps of preparing the platelet simulating particles are the same as that for the reticulocyte simulating particles. The preparation method comprises: using an protein fluorescent dye activated by N-hydroxysuccinimide to stain mammalian anucleated red blood cells having different volumes, so as to respectively obtain reticulocyte simulating particles and platelet simulating particles.

The present disclosure relates to synthetic Plasmodium reticulocyte binding protein 2b (mRBP2b) antigens that have improved properties such as thermal stability, as well as the use of these antigens to detect a Plasmodium infection in a diagnostic device or for use in a vaccine.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to application of a qi-tonifying and blood-maintaining preparation in preparation of a medicine for treating thalassemia. Researches show that the preparation for tonifying qi and maintaining blood is used for treating thalassemia and can effectively improve the anemia state and iron metabolism disorder of patients. Specifically, the medicine can significantly improve the hemoglobin level, increase the red blood cell count and the red blood cell average volume, and improve the serum iron content, the ferritin content and the reticulocyte proportion. The results show that the qi-tonifying and blood-maintaining preparation has the effect of promoting the bone marrow hematopoiesis function and can regulate and optimize the iron metabolism process. The invention provides an economical, effective and convenient treatment scheme for the thalassemia patient.

This invention relates to erythroid cells, such as reticulocyte cells, engineered to express a variant protein which comprises one or more mutations which increase the level of the variant protein in the cytosol of the cells. The invention also relates to erythroid cells, such as reticulocyte cells, genetically engineered to overexpress antioxidant proteins and / or an intrinsically disordered proteins (IDPs) in their cytosol and variants of such proteins which facilitate their overexpression in the cytosol of cells. Modification of the cells in this way enhances their storage, whether by refrigeration, freezing, lyophilisation or another storage method. The cells of the invention can be used to deliver therapeutic proteins or polypeptides.

This invention relates to antibodies for the treatment or prevention of malaria.

Disclosed are a blood analysis system, method, device, and computer storage medium. The blood analysis system includes: a sample collection device for collecting a blood sample and transferring the blood sample to a sample preparation device; a sample preparation device for processing the blood sample using a reagent to prepare a sample solution to be tested; an impedance detection device for detecting the sample solution to be tested to obtain an impedance pulse signal of cells in the sample solution to be tested; and a data processing device for performing the following steps: obtaining a blood cell histogram of the sample solution to be tested based on the impedance pulse signal, inputting the blood cell histogram into a pre-trained deep learning neural network model to obtain blood cell parameters output by the deep learning neural network model, wherein the blood cell parameters are at least one of the following: a reticulocyte parameter, a reticulocyte platelet parameter, and a red blood cell fragment parameter; and the deep learning neural network model is obtained by training blood training samples labeled with blood cell parameters using a machine learning algorithm.

The present invention relates to a method of maturity classifying reticulocytes from a whole blood sample, comprising: staining the sample with a supravital agglutinating dyeing reagent or a fluorescent agglutinating dye; illuminating the stained sample with a light beam to detect reticulocytes; determining for each reticulocyte the parameters of (i) a fraction (Λ) of the reticulum area (Ar) to the whole cell area (Ac); and (ii) a fraction (Γ) of the perimeter of the reticulum (Ur) to the reticulum area (Ar); and maturity classifying a reticulocyte into 1 of 4 major maturity classes according to the values determined for Λ and Γ.

The present invention relates to the use of light microscopy for reticulocyte maturity classification of stained reticulocytes. In particular, the present invention relates to a method for reticulocyte maturity classification from a whole blood sample, comprising: staining the sample with a supravital agglutination stain reagent or a fluorescent agglutination dye; illuminating the stained sample with a light beam to detect reticulocytes; determining for each reticulocyte the parameters (i) the fraction of reticular area (Ar) relative to the whole cell area (Ac) (Λ) and (ii) the fraction of reticular perimeter (Ur) relative to the reticular area (Ar) (Γ); and classifying the reticulocyte maturity into one of four main maturity classes according to the determined Λ and Γ values.

Provided are a method for preparing reticulocyte simulating particles and platelet simulating particles, and a reference control. The method for preparing the reticulocyte simulating particles comprises: staining mammalian anucleated red blood cells having a volume of 60-120 fL with a protein fluorescent dye activated by N-hydroxysuccinimide, and fixing the anucleated red blood cells to prepare the reticulocyte simulating particles. The platelet simulating particles are prepared from mammalian anucleated red blood cells having a volume of 2-25 fL, and the steps of preparing the platelet simulating particles are the same as that for the reticulocyte simulating particles. The preparation method comprises: using an protein fluorescent dye activated by N-hydroxysuccinimide to stain mammalian anucleated red blood cells having different volumes, so as to respectively obtain reticulocyte simulating particles and platelet simulating particles. The fluorescence and volume direction thereof in the scatter diagram are similar to the scatter diagram distribution of reticulocytes, reticulated platelets and platelets in fresh blood. The prepared simulating particles have good stability and do not interfere with the counting and differentiation of other cell particles.

The application discloses a reticulocyte identification and grading system based on blood smears, and particularly relates to the field of medical cell morphology inspection, and comprises an image acquisition module, a staining normalization module, an instance segmentation module, an erythrocyte classification module, a reticulocyte grading module and a statistical output module; the image acquisition module: adopts an automatic microscope platform to continuously scan blood smears under a 100-fold field of view, collects high-quality bright field channel images through automatic focusing technology, and monitors image definition, contrast and illumination uniformity; the statistical output module: calculates the proportion of reticulocytes at all levels and blue-purple intensity statistics, and generates visual quality control results and diagnosis reports; the application realizes full-automatic processing from samples to reports, takes into account interpretability and high classification accuracy, significantly reduces subjective differences and missed detection rates of manual microscopy, and improves the efficiency and consistency of clinical detection.

The present invention provides the use of 18β-glycyrrhetinic acid for improving the hematopoietic capacity of renal anemia. The present invention discovers and verifies for the first time that 18β-glycyrrhetinic acid stimulates the production of endogenous EPO, thereby improving the body's hematopoietic capacity. Short-term supplementation of 18β-glycyrrhetinic acid can significantly increase the level of erythropoietin, thereby promoting the production of reticulocytes. Long-term supplementation of 18β-glycyrrhetinic acid can improve indicators such as red blood cell count and alleviate the symptoms of renal anemia. The present invention provides a natural, safe, and highly effective active ingredient that improves the body's hematopoietic capacity, provides a scientific basis for basic research on drugs for the clinical treatment and prevention of renal anemia, and has significant application value.

The invention relates to a blood cell analyzer and a blood cell analysis method. The method comprises the following steps: mixing a part of a sucked blood sample to be detected, a diluent and a fluorescent staining agent in a first reaction tank to prepare a first determination sample, and obtaining first optical information generated after particles in the first determination sample are irradiated by light; mixing the other part of the blood sample to be detected with a hemolytic agent in a second reaction tank to prepare a second determination sample, and obtaining colorimetric optical information of the second determination sample; obtaining a reticulocyte detection result, a platelet detection result, an erythrocyte detection result and a first leukocyte detection result of the to-be-detected blood sample based on the first optical information, wherein the first leukocyte detection result at least comprises a lymphocyte percentage, a mononuclear cell percentage and a granulocyte percentage; and determining the hemoglobin concentration of the to-be-detected blood sample based on the colorimetric method optical information. According to the application, the reagent cost required for obtaining the detection result of the to-be-detected blood sample can be reduced.

This invention relates to erythroid cells, such as reticulocyte cells, engineered to express a variant protein which comprises one or more mutations which increase the level of the variant protein in the cytosol of the cells. The invention also relates to erythroid cells, such as reticulocyte cells, genetically engineered to overexpress antioxidant proteins and / or an intrinsically disordered proteins (IDPs) in their cytosol and variants of such proteins which facilitate their overexpression in the cytosol of cells. Modification of the cells in this way enhances their storage, whether by refrigeration, freezing, lyophilisation or another storage method. The cells of the invention can be used to deliver therapeutic proteins or polypeptides.

The invention discloses a fluorescent dye composition and application thereof in biological sample dyeing, a reticulocyte detection reagent comprises a dye reagent and a diluent, and an anionic surfactant and an anionic compound contained in a buffer solution are utilized to reduce the thickness of a cell membrane and accelerate the rate that a fluorescent dye permeates into cells, so that the detection sensitivity of the reticulocyte is improved. Meanwhile, non-specific binding of the dye and red blood cells can be inhibited, several kinds of non-nucleic acid specific dyes are added, and a large number of binding competitive relations existing in a reaction system are adjusted by controlling the proportion of the added main dye to the added auxiliary dye and increasing reaction kinetics between nucleic acid and the dyes; the possibility of combining non-specific binding sites of a blood mixture through competition of secondary staining and primary staining is achieved, the fluorescence background is reduced, RBC fragments and low-fluorescence PLT are effectively distinguished, and the counting accuracy of the PLT is improved; high-fluorescence RET and leukocytes can be effectively distinguished, and RET classification counting accuracy is improved.

The invention specifically discloses a method and a system for predicting thrombocytopenic purpura, electronic equipment and a storage medium, and relates to the technical field of biological medicines. The invention provides a new prediction model (including platelet count, reticulocyte percentage, indirect bilirubin, broken red blood cells and a ratio of lactic dehydrogenase to normal high value) to help clinicians to early identify TTP patients, improve the TTP diagnostic rate, reduce the misdiagnosis rate, and improve the accuracy of TTP diagnosis on the basis of improving the diagnostic rate. The method has important guiding significance in the aspects of early treatment of patients, improvement of prognosis and the like.

The invention provides a preparation method of polyethylene glycol amphotericin B micelles, and belongs to the field of biological medicine manufacturing. The method comprises the following steps: reacting methoxy polyethylene glycol with lactide at 110-130 DEG C for 6-12 hours to obtain a block copolymer; the segmented copolymer and 2-(diisopropylamino) ethylamine are subjected to a reaction for 12-24 h, and a terpolymer is obtained; the terpolymer and 4-(hydroxymethyl) phenylboronic acid pinacol ester are subjected to a reaction for 12-36 h, and a quadripolymer is obtained; co-loading the quadripolymer and amphotericin B to obtain a micelle core; extracting a denucleated reticulated erythrocyte membrane from whole blood; and wrapping the outer surface of the micelle core with the denucleated reticulated erythrocyte membrane to obtain the polyethylene glycol amphotericin B micelle. Through the step-by-step design of intelligent response drug loading and bionic delivery camouflage, the dual purposes of'curative effect improvement and toxicity reduction 'of amphotericin B are achieved from three dimensions of accurate drug release, effective focus enrichment and normal tissue protection.

A method, just requiring simple pretreatment, of concentration measurement for reticulocytes or nucleated erythrocytes includes a staining step, a removal step, and a measurement step. In the staining step, reticulocytes or nucleated erythrocytes among red blood cells contained in a blood specimen are stained. In the removal step, the blood specimen is mixed with a surfactant to extract hemoglobin from the red blood cells. In the measurement step, using the blood specimen having undergone the staining step and the removal step, the concentration of the reticulocytes or nucleated erythrocytes contained in the blood specimen is measured.

A method for dilution of a blood sample for analysis and to an apparatus for implementation of this method is provided.In the method, an aliquoting device is used, making it possible to carry out a single collection, to form a first dilution in a chamber, to collect a portion of the first dilution in order to form a second dilution in another chamber, to count the blood cells in the first and the second chamber, to carry out a differentiation based on the first dilution, to rinse the first chamber, to form a third dilution based on a quantity of first-dilution liquid remaining in the aliquoting device, then to carry out a differentiation of reticulocytes based on this third dilution.

The present application relates to a blood cell analyzer and a blood cell analysis method. One part of a suctioned blood sample to be detected, a diluent and a fluorescent coloring agent are mixed in a first reaction tank to prepare a first measurement sample, and first optical information generated by particles in the first measurement sample when said particles are irradiated by light is obtained; the other part of said blood sample and a hemolytic agent are mixed in a second reaction tank to prepare a second measurement sample, and colorimetric method optical information of the second measurement sample is obtained; a reticulocyte detection result, a platelet detection result, an erythrocyte detection result and a first leukocyte detection result of said blood sample are obtained on the basis of the first optical information, the first leukocyte detection result at least comprising a lymphocyte percentage, a monocyte percentage and a granulocyte percentage; and the hemoglobin concentration of said blood sample is determined on the basis of the colorimetric method optical information. The present application allows for reduction of the reagent costs required for obtaining the detection result of a blood sample to be detected.

The present invention provides a method for producing reticulocytes containing increased levels of target protein or polypeptide. [Solution] The method comprises (a) preparing a erythrocyte precursor capable of expressing the target protein or polypeptide, (b) expressing the target protein or polypeptide, and (c) maturing the erythrocyte precursor into a reticulocyte, wherein the target protein or polypeptide is configured and / or inhibited so as to interfere with or prevent ubiquitination of the target protein or polypeptide when the erythrocyte precursor is matured into a reticulocyte. Erythrocytes, pharmaceutical compositions and related methods of use, as well as a method for screening proteins or polypeptides that are degraded by ubiquitination during the maturation of erythrocyte precursors, are also provided.

The invention discloses an asymmetric cyanine derivative compound, a reagent containing the asymmetric cyanine derivative compound and application of the asymmetric cyanine derivative compound to reticulocyte determination. The asymmetric cyanine derivative compound comprises two nitrogen-containing heterocyclic rings including benzothiazole / oxazole and dihydroquinoline and conjugated double bonds connecting the two nitrogen-containing heterocyclic rings. According to the invention, alkoxy is introduced to a dihydroquinoline ring for modification, tertiary amine is introduced to a benzothiazole / oxazole ring for modification, and the length of a carbon chain between a modification group and a main structure is controlled at the same time. The three modification elements play a synergistic role, so that the combining capacity of the asymmetric cyanine derivative compound and nucleic acid substances is improved, the fluorescence performance of the compound after being combined with the nucleic acid substances is greatly enhanced, and meanwhile, the structural stability of the compound is enhanced. The RET reagent prepared from the compound provided by the invention has excellent reticulocyte detection performance.

The application discloses an image processing method and device for judging hemolysis of suspended red blood cells, and the method comprises the following steps: acquiring a blood image set; the blood image set comprises a plurality of blood images and corresponding label information; acquiring a blood parameter information set; the blood parameter information set comprises a plurality of blood parameters and corresponding label information; the blood parameters comprise hemoglobin concentration, reticulocyte concentration, indirect bilirubin concentration, lactate dehydrogenase concentration and globin concentration; a blood hemolysis composite detection model is constructed by using the blood image set and the blood parameter information set; the collected blood image and blood parameter are processed based on the blood hemolysis composite detection model, and hemolysis detection result information is obtained; the hemolysis detection result information is used for representing the red blood cell hemolysis information of the corresponding blood of the collected blood image and blood parameter.

To provide a means for delivering to the brain an effector function positive therapeutic agent that does not cause reticulocyte loss.SOLUTION: The present disclosure generally provides an Fc polypeptide dimer comprising a non-native transferrin receptor (TfR) binding site, wherein the Fc polypeptide dimer does not substantially deplete reticulocytes in vivo, but retains binding to an Fey receptor (FcyR). The present disclosure also provides an Fc polypeptide dimer wherein one of the Fc polypeptides comprises a non-native site that specifically binds TfR and a modification (s) in the Fc polypeptide comprising the TfR binding site that reduces binding of an Fc γ R when bound to TfR, wherein the other Fc polypeptide does not comprise a TfR binding site but retains binding to an Fc γ R.SELECTED DRAWING: None

There are provided antibodies and combination thereof, and other binding proteins against malarial antigens, as well as said antigens and vectors encoding the antibodies and antigens. The invention also provides the use of such compounds and combinations thereof in the prevention or treatment of malaria. In particular, synergistic combinations of non-neutralising antibodies directed towards an epitope on Reticulocyte-binding protein Homologue 5 (PfRH5) and neutralising antibodies directed towards Plasmodium merozoite antigens are provided.

This provides a novel therapeutic agent that can target HER2 in the brain parenchyma, transcending the blood-brain barrier (BBB). [Solution] In some embodiments, anti-HER2 constructs (e.g., Fc polypeptide dimer-antibody variable region fusion proteins) retain effector function upon binding to HER2 but do not substantially reduce reticulocytes in vivo. The disclosure also relates to methods for transcytosis of anti-HER2 antibody variable regions across the blood-brain barrier to treat HER2-positive cancers and their metastatic lesions.

The invention discloses a transdifferentiation immunologic function of nucleated red blood cells of an ARDS patient and application of the transdifferentiation immunologic function, and belongs to the field of biomedicine. The first aspect of the invention relates to application of a reagent for detecting reticulocyte damage and / or a reagent for detecting T cell markers carried by nucleated red blood cells in preparation of a kit for diagnosing acute respiratory distress syndrome. On the second aspect, the invention relates to a method for detecting differentiation of nucleated red blood cells, which comprises the following steps: screening nucleated red blood cells which grow later; and detecting and / or counting nucleated red blood cells with T cell markers in nucleated red blood cells with later development. The invention discloses the differentiation phenomenon of nucleated red blood cells, and the nucleated red blood cells can be applied to the research of the ARDS process and the diagnosis of ARDS.